These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. Cohen MS; Nirula A; Mulligan MJ; Novak RM; Marovich M; Yen C; Stemer A; Mayer SM; Wohl D; Brengle B; Montague BT; Frank I; McCulloh RJ; Fichtenbaum CJ; Lipson B; Gabra N; Ramirez JA; Thai C; Chege W; Gomez Lorenzo MM; Sista N; Farrior J; Clement ME; Brown ER; Custer KL; Van Naarden J; Adams AC; Schade AE; Dabora MC; Knorr J; Price KL; Sabo J; Tuttle JL; Klekotka P; Shen L; Skovronsky DM; JAMA; 2021 Jul; 326(1):46-55. PubMed ID: 34081073 [TBL] [Abstract][Full Text] [Related]
9. PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together. Ernest CS; Chien JY; Patel DR; Chigutsa E CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):721-730. PubMed ID: 35289125 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study. Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E; Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429 [TBL] [Abstract][Full Text] [Related]
11. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701 [TBL] [Abstract][Full Text] [Related]
12. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. Choudhary MC; Chew KW; Deo R; Flynn JP; Regan J; Crain CR; Moser C; Hughes MD; Ritz J; Ribeiro RM; Ke R; Dragavon JA; Javan AC; Nirula A; Klekotka P; Greninger AL; Fletcher CV; Daar ES; Wohl DA; Eron JJ; Currier JS; Parikh UM; Sieg SF; Perelson AS; Coombs RW; Smith DM; Li JZ; Nat Microbiol; 2022 Nov; 7(11):1906-1917. PubMed ID: 36289399 [TBL] [Abstract][Full Text] [Related]
13. Atrial fibrillation with aberrant ventricular conduction after receiving Bamlanivimab/Etesevimab: a case report. Palazzo AG; Zizza A; Nuzzo M; Urciuoli C; Scardia S; Romano A; Guido M; Grima P Curr Med Res Opin; 2022 Jul; 38(7):1055-1057. PubMed ID: 35608093 [TBL] [Abstract][Full Text] [Related]
14. The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. Benschop RJ; Tuttle JL; Zhang L; Poorbaugh J; Kallewaard NL; Vaillancourt P; Crisp M; Trinh TNV; Freitas JJ; Beasley S; Daniels M; Haustrup N; Higgs RE; Nirula A; Cohen MS; Marovich M Sci Transl Med; 2022 Jul; 14(655):eabn3041. PubMed ID: 35679357 [TBL] [Abstract][Full Text] [Related]
15. Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial. Chew KW; Moser C; Daar ES; Wohl DA; Li JZ; Coombs R; Ritz J; Giganti M; Javan AC; Li Y; Malvestutto C; Klekotka P; Price K; Nirula A; Fischer W; Bala V; Ribeiro RM; Perelson AS; Fletcher CV; Eron JJ; Currier JS; Hughes MD; Smith DM; medRxiv; 2021 Dec; ():. PubMed ID: 34981077 [TBL] [Abstract][Full Text] [Related]
16. Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses. Ramirez SI; Grifoni A; Weiskopf D; Parikh UM; Heaps A; Faraji F; Sieg SF; Ritz J; Moser C; Eron JJ; Currier JS; Klekotka P; Sette A; Wohl DA; Daar ES; Hughes MD; Chew KW; Smith DM; Crotty S; JCI Insight; 2022 Dec; 7(24):. PubMed ID: 36378539 [TBL] [Abstract][Full Text] [Related]
17. Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis. Thomas S; Smatti MK; Ouhtit A; Cyprian FS; Almaslamani MA; Thani AA; Yassine HM Mol Immunol; 2022 Dec; 152():172-182. PubMed ID: 36371813 [TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab. Heller M; Henrici C; Büttner J; Leube S; Treske I; Pospischil P; Doll M; Schanz I; Hallier A; Herrmann E; Schmidt M; Sarrazin C Int J Infect Dis; 2023 Apr; 129():260-265. PubMed ID: 36690138 [TBL] [Abstract][Full Text] [Related]
19. In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG. Wang X; Li M; Lu P; Li C; Zhao C; Zhao X; Qiao R; Cui Y; Chen Y; Li J; Cai G; Wang P Pathogens; 2023 Aug; 12(9):. PubMed ID: 37764916 [TBL] [Abstract][Full Text] [Related]